Last quarter (Q3 2023), Finch Therapeutics Group's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Finch Therapeutics Group's net income was $-2.42M. See Finch Therapeutics Group’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 1.07M	$ 861.00K	$ 18.53M	$ 7.72M	$ 10.15M
Cost of Revenue	$ -10.00M	$ 5.00M	-	$ 0.00	$ 314.00K
Gross Profit	$ 1.07M	$ 861.00K	$ 18.53M	$ 7.72M	$ 9.84M
Operating Expense	$ 36.21M	$ 116.45M	$ 78.52M	$ 47.16M	$ 30.98M
Operating Income	$ -91.37M	$ -115.59M	$ -59.98M	$ -39.44M	$ -21.14M
Net Non Operating Interest Income Expense	$ 1.10M	$ -4.00K	$ 1.85M	$ 106.00K	$ 488.00K
Other Income Expense	$ 9.23M	$ -947.00K	$ 24.00K	$ -11.00K	$ -100.00K
Pretax Income	$ -103.77M	$ -114.65M	$ -58.16M	$ -39.34M	$ -20.75M
Tax Provision	$ -3.46M	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -37.24M	$ -114.65M	$ -58.16M	$ -39.34M	$ -20.75M
Basic EPS	$ -8.72	$ -2.40	$ 0.00	$ -1.13	$ -0.60
Diluted EPS	$ -7.72	$ -2.40	$ -44.40	$ -1.13	$ -0.60
Basic Average Shares	$ 98.99M	$ 47.69M	$ 1.31M	$ 34.69M	$ 34.69M
Diluted Average Shares	$ 98.99M	$ 47.69M	$ 1.31M	$ 34.69M	$ 34.69M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 26.21M	$ 121.45M	$ 78.52M	$ 47.16M	$ 31.30M
Net Income From Continuing And Discontinued Operation	$ -100.31M	$ -114.65M	$ -58.16M	$ -39.34M	$ -20.75M
Normalized Income	$ -7.28M	$ -70.09M	-	$ -39.33M	$ -20.61M
Interest Expense	-	-	-	-	-
EBIT	$ -104.46M	$ -114.64M	$ -58.17M	$ -39.44M	$ -21.14M
EBITDA	$ -101.59M	$ -109.14M	$ -55.87M	$ -38.65M	$ -20.66M

Currency in USD

Finch Therapeutics Group Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing